|
| Progenics And Wyeth Announce FDA Has Approved RELISTOR |
5 May 08, 14:07 |
|
| Progenics Pharmaceuticals, Inc. and Wyeth Pharmaceuticals, a division of Wyeth , recently announced that the U.S. Food and Drug Administration (FDA) has approved RELISTOR (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been ... |
| more |
|
